APA (7th ed.) Citation

Harter, P., Trillsch, F., Okamoto, A., Reuss, A., Kim, J., Rubio-Pérez, M., . . . Marquina, G. (2026). Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer. Annals of Oncology, 37(4), 503. https://doi.org/10.1016/j.annonc.2025.11.020

Chicago Style (17th ed.) Citation

Harter, P., et al. "Durvalumab with Carboplatin/paclitaxel and Bevacizumab Followed by Durvalumab and Bevacizumab with or Without Olaparib Maintenance in Newly Diagnosed Non-BRCA-mutated Advanced Ovarian Cancer." Annals of Oncology 37, no. 4 (2026): 503. https://doi.org/10.1016/j.annonc.2025.11.020.

MLA (9th ed.) Citation

Harter, P., et al. "Durvalumab with Carboplatin/paclitaxel and Bevacizumab Followed by Durvalumab and Bevacizumab with or Without Olaparib Maintenance in Newly Diagnosed Non-BRCA-mutated Advanced Ovarian Cancer." Annals of Oncology, vol. 37, no. 4, 2026, p. 503, https://doi.org/10.1016/j.annonc.2025.11.020.